COMPANY PROFILE / #1538
CytoReason
Tel Aviv, IsraelVenture Capital-Backed
OVERVIEW
Developer of an AI-powered computational disease modeling platform designed to accelerate drug research and development. The company's platform integrates molecular, clinical, and patient-level data into computational disease models that map disease mechanisms, treatments, and patient populations at the cellular and tissue levels, enabling pharmaceutical and biotechnology companies to identify therapeutic targets, stratify patients, compare treatments, and make data-driven drug development decisions.
已融资123.03
最新估值159.82
员工数107
成立年份2016
公司概况
- Companies
- CytoReason
- Description
- Developer of an AI-powered computational disease modeling platform designed to accelerate drug research and development. The company's platform integrates molecular, clinical, and patient-level data into computational disease models that map disease mechanisms, treatments, and patient populations at the cellular and tissue levels, enabling pharmaceutical and biotechnology companies to identify therapeutic targets, stratify patients, compare treatments, and make data-driven drug development decisions.
- Website
- www.cytoreason.com
- HQ Location
- Tel Aviv, Israel
- Year Founded
- 2016
- Keywords
- bioinformatics analysis, bioinformatics data, biomarker discovery platform, cancer immunotherapy, cellular biology, clinical development, computational disease modelling, computational modeling, data analysis, disease modeling, healthcare technology, patient stratification
- Competitors
- Quris AI, Protai Bio, Pepticom
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 123.03
- First Financing Date
- 01-Jan-2020
- First Financing Size
- 10.00
- First Financing Valuation
- 12.26
- Last Financing Date
- 15-Jul-2024
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 80.00
- Last Financing Valuation
- 159.82
- Last Financing Status
- Completed
- Last Known Valuation
- 159.82
- Last Known Valuation Date
- 15-Jul-2024
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 216.10
- Valuation Estimate Growth Rate
- 35.22%
- Active Investors
- Astarc Ventures, Asymmetry Ventures, IM Infinity Innonation, M&G, Nvidia, OurCrowd, Pfizer, PICO Venture Partners, Pontifax Venture Capital, Thermo Fisher Scientific
- # Active Investors
- 10
- Acquirers
- —
团队与联系人
- Employees
- 107
- Employee Growth %
- -17.05%
- Employee History
- 2026: 107, 2025: 129, 2024: 128, 2023: 138, 2022: 80, 2021: 62, 2020: 43
- Primary Contact
- David Harel
- Primary Contact Title
- Co-Founder, Chief Executive Officer, President & Board Member
- Primary Contact Email
- david@cytoreason.com
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- -0.27%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 9
- Size Multiple
- 12.51x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 94
- Majestic Referring Domains
- 303
- SimilarWeb Unique Visitors
- 141
- SimilarWeb Unique Visitors Change
- -42
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 18%
- Success Probability Over Time – 3 Year
- 37%
- Success Probability Over Time – 5 Year
- 54%
记录来源：public.companies · 原始序号 #1538 · 所有字段均按数据库原值展示。